1 / 4

Germany Myocardial Infarction Market

Germany Myocardial Infarction Market

farazp70
Download Presentation

Germany Myocardial Infarction Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research Germany Myocardial Infarction Market Size, Share, Growth, Industry Analysis Report and Forecast to 2025 Request a free sample of our report on Germany Myocardial Infarction Market: https://www.omrglobal.com/request-sample/germany-myocardial-infarction-market ------------------------------------------------------------------------------------ Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803040404

  2. Germany myocardial infarction (MI) market is estimated to grow considerably, at a CAGR of around 5.4% during the forecast period. Germany has a considerable market share of the global MI treatment market due to the massive population of CVD, CHD, MI, and stroke, and the rise in the adoption of cardiology surgeries for Angioplasty and CABG surgeries. Germany has a quality healthcare system and favorable government policies which are driving the MI treatment market in the country. It has a quality healthcare system, which is equipped with the latest cardiology devices and products such as innovative stents, catheters, and guidewires. Adoption of innovative cardiology surgeries in major hospitals, research centres, and clinics enable to provide better patient care and treatment. However, the healthcare system of Germany is costly and there is no reimbursement for the heart transplant and other critical cardiology surgeries such as MI and CVD. Get Sample Copy of Germany Myocardial Infarction Market at:https://www.omrglobal.com/request- sample/germany-myocardial-infarction-market The companies which are contributing to the growth of the Germany myocardial infarction market include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Novartis AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end- user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes. For More Information, get A full report of Germany Myocardial Infarction Market is available at: https://www.omrglobal.com/industry-reports/germany-myocardial-infarction-market The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in November 2018, Bayer and Merck’s Investigational drug Vericiguat meet the primary endpoint in phase III study of patients with worsening chronic heart failure. Vericiguat reduced the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction, compared to placebo when added to available heart failure therapies. Market Segmentation Germany Myocardial Infarction Market by Type •Non-ST-elevation myocardial infarction (NSTEMI) •ST-elevation myocardial infarction (STEMI)

  3. •Silent Heart Attacks Germany Myocardial Infarction Market by Device •Left Ventricular Assist Device (LVAD) •Pacemaker •Catheters •Implantable Cardioverter-Defibrillator (ICD) •Others (Stent Graft) Germany Myocardial Infarction Market by Diagnosis •Electrocardiography (ECG) •Chest X-Ray •Computed Tomography (CT Scan) •Echocardiography •Others (Blood Test) Germany Myocardial Infarction Market by Treatment •Medication •Analgesics •Thrombolytic •Antiplatelet Agents •Glycoprotein IIb/IIIa Inhibitors •Others (Beta-Adrenergic Blockers) •Surgery •Angioplasty •Bypass Surgery •Heart Transplant Germany Myocardial Infarction Market by End-User •Hospital & Clinics •Ambulatory Surgical Centers •Research Institutes For more customized data, request for report customization @https://www.omrglobal.com/report- customization/germany-myocardial-infarction-market About Orion Market Research

  4. Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research- based services. For More Information, Visithttps://www.omrglobal.com/ Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803040404

More Related